Audent Global Asset Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
Other funds holding IBB
CB
Audent Global Asset Management's IBB Position: Q2 2026 in Review
Audent Global Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 40% in Q2 2026, selling an estimated $1.03M and leaving 9,167 shares worth $1.74M. The position accounts for 1.95% of the portfolio, ranked #19.
Audent Global Asset Management first reported a position in IBB in Q4 2021 and has held it in 19 quarters since. The position peaked at $8.15M in Q4 2021. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Audent Global Asset Management held 9,167 shares of iShares Biotechnology ETF worth $1.74M as of Q2 2026.
- Audent Global Asset Management sold 6,018 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.03M.
- iShares Biotechnology ETF made up 1.95% of Audent Global Asset Management's portfolio in Q2 2026, its #19 holding.
- Audent Global Asset Management first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 19 quarters since.
- Audent Global Asset Management's iShares Biotechnology ETF position peaked at $8.15M in Q4 2021.
- 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Audent Global Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.